Royalty Report: Drugs, Diagnostic, Diagnostic Substances – Collection: 7069


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Diagnostic
  • Diagnostic Substances
  • Biotechnology
  • Cancer
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7069

License Grant
The Licensor hereby grants the Licensee an exclusive License to make, have made, use, import, offer for sale and sell the Licensed Products and to provide the Licensed Services in the United States and worldwide.
License Property
This grant shall apply to the Licensee and any affiliated company, except that any affiliated company shall not have the right to subLicense others

The Invention is entitled Albumin-Bound Protein/Peptide Complex As A Biomarker For Disease, International Application, PCT/US2007/013968, filed on June 14, 2007, and assigned to the Licensor.

Patent Rights shall mean the International Application, PCT/US2007/013968, filed on June 14, 2007, and assigned to JHU entitled Albumin-Bound Protein/Peptide Complex As A Biomarker For Disease, and the invention disclosed and claimed therein, national stage applications, and all continuations, divisions, and reissues based thereon, and any corresponding foreign patent applications, and any patents, or other equivalent foreign Patent Rights issuing, granted or registered thereon.

Field of Use
A method of diagnosing a disease or disorder in a subject, comprising (a) measuring the level of at least one biomarker in a biological sample obtained from said subject, wherein said biomarker comprises an albumin-bound protein/peptide complex (ABPPC), and (b) comparing the level measured in the biological sample to a control level in a normal subject population, wherein an increase or decrease in the level, compared to control level, is indicative of said disease or disorder.

IPSCIO Record ID: 2662

License Grant
The Licensor hereby grants to the Licensee a license under Licensor's Patent Rights to make, have made, use, and sell Licensed Products within the United States and elsewhere throughout the world.
License Property
Licensor's Patent Rights, as used herein, means patent rights to any subject matter claimed in or covered by any of the following (a) U.S. Patent Nos. 4,572,203 entitled Contact (SIC) Agents for Ultrasonic Imaging issued February 25, 1986 (Appendix B),4,718,433, issued January 12, 1988, and 4,774,958, issued October 4, 1988, and any U.S. Patents resulting from the reissue or reexamination thereof; (b) Any current continuing or continuation-in-part applications or future continuing applications thereof; (c) Any patents issuing on said  applications or continuing or continuation-in-part applications thereof, including reissues; and (d) Any corresponding foreign patents or applications therefor.  The term Licensed Products, as  used herein, means any product, apparatus, kit or component part thereof, or other subject matter whose manufacture, use, or sale is covered by any claim or claims included within Licensor's Patent Rights.
Field of Use
The rights granted apply to the field of ultrasonic imaging and medical procedures.

IPSCIO Record ID: 4269

License Grant
University hereby grants to Licensee an exclusive, worldwide License under Licensor’s rights including the right to grant subLicenses, to the Licensed Patent Rights to develop, and commercialize Licensed Products in the territory, in all fields of use.
License Property
Licensed Patent Rights
USSN 61/484330, filed May 10, 2011, entitled Hairy Cell Leukemia Biomarkers and Methods of Using Same.
Field of Use
Hairy cell leukemia (HCL) is a hematological malignancy characterized by an accumulation of abnormal B lymphocytes. It is usually classified as a sub-type of chronic lymphoid leukemia. HCL was originally described as histiocytic leukemia, malignant reticulosis, or lymphoid myelofibrosis. The disease was formally named leukemic reticuloendotheliosis and its common name is derived from the 'hairy' appearance of the malignant B cells under a microscope.
The present invention provides, in part, a method of diagnosing hairy cell leukemia in a subject in need thereof including obtaining a biological sample from the subject and assessing the presence or absence of a BRAF mutation in the sample, wherein the presence of the BRAF mutation indicates that the subject is suffering from hairy cell leukemia. [0006] The method can further include comparing the presence, absence, or amount of the BRAF mutation in the biological sample with the presence, absence, or amount of the BRAF mutation determined in a biological sample from a subject not suffering from hairy cell leukemia or symptoms thereof. The method can be used to distinguish hairy cell leukemia cells from other forms of malignant lymphoma.

IPSCIO Record ID: 4026

License Grant
The Licensor, an individual, hereby grants to the Licensee an exclusive License, within the worldwide territory, except Japan, to utilize the Technology to develop, manufacture, use, promote to sell, and sell any Products during the term of this License Agreement. The Licensee shall not subLicense such rights to any third parties without prior written consent of the Licensor.
License Property
The Licensor is willing to grant access to all information in his possession regarding methods for the determination of oxidized lipoproteins and access to all related analytes, antibodies and antigens, existing as of the date of this License Agreement and any and all improvements or future developments related thereto, including those related to the Patents or the Japanese Patents to develop any human diagnostic products to be manufactured and sold by Corgenix, including those that include the Patents or the Japanese Patents.

Licensed Patents
5,900,359; 7,160,733; 7,422,864; 7,455,976; 1 548 436; 04713170
Japanese Patents 07-510213; PCT/JP02/00723; 2002-261366

Field of Use
The exclusive rights granted relates to the methods to determine oxidized lipoproteins and related analytes, antibodies and antigens.

IPSCIO Record ID: 7117

License Grant
The Sub-Licensor is the exclusive licensee of the Patent Rights relating to the Field under the Exclusive License Agreement dated May 2006, and is willing to grant to the Sub-Licensee a non-exclusive, royalty-bearing Sublicense in the Territory to use such Patent Rights in the Field.
License Property
The Sub-Licensee shall have no right to further sublicense.

Patent Rights shall mean Patent Application PCT/IT2005/000634 filed October 28, 2005 entitled Nucleophosmin protein (NPM) mutants, corresponding gene sequences and uses thereof (published as WO 2006/046270), and foreign equivalents, including Canadian Patent Application 2585965 as well as all continuations, divisions, reissues, reexaminations, renewals, or extensions of such patents subject to the rights granted by Original Licensor pursuant to the Exclusive License Agreement, as limited by this Agreement.

Field of Use
Field shall mean identification and diagnosis, including monitoring of minimal residual disease, of nucleophosmin protein (NPM1) mutations in bone marrow, blood cells, and other cellular specimens. Specifically excluded is testing of urine or any other cell free specimen. The Field specifically includes IVD Laboratory Services testing and use of NPM1 as a drug target.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.